The leading European partnering event for early-stage deals and investment rounds in the field of Life Sciences

DECEMBER 4TH & 5TH 2018

LILLE France
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.

BioFIT 2018 Key Figures:

- **1,200** delegates
- **800** organisations
- **35** countries represented
- **100** exhibitors
- **80** high-level speakers

BioFIT is organised by:

**Institutional partners:**

Etienne Vervaecke  
General Manager of Eurasanté and the NHL Cluster

Emilie Royere  
General Manager of Eurobiomed

Marco Pintore  
General Manager of BioValley France

«BioFIT has emerged as the leading partnering event in Europe to source early-stage innovations and collaborative research capacities in Life Sciences, and also to obtain funding for seed rounds. Today, we are very pleased to welcome you in Lille for this 7th edition and glad to announce that BioFIT will be organised alternately in Marseille (2019), in Strasbourg (2020) and in Lille (2021). This unique partnership between these 3 French ecosystems will enable BioFIT audience to enjoy both a new venue and a new destination.

Drawing on the strengths and assets of each territory in which BioFIT is now based, the event is strengthening its position as a leading partnering event in Europe, and thus, better provides you a complete framework for exchanges that can intensify your interactions and significantly increase partnerships and funding opportunities for the development of your projects.

We hope that you will take full part in all the activities of this pivotal edition and that we will meet you next year in Marseille on December 10th and 11th, 2019 and then in Strasbourg in December 2020, for even more meetings, deals and discoveries of early-stage innovations in Life Sciences!»

WELCOME
STEERING COMMITTEE

MARIA BOBADILLA
SPECIAL DIRECTOR, INNOVATION NETWORKS, ROCHE

ADRIAN CARTER
CORPORATE VICE PRESIDENT AND GLOBAL HEAD OF DISCOVERY RESEARCH COORDINATION, BOURNEHUR DINGELHEIM

SAMIT TCHAOOUROU
EXECUTIVE VICE PRESIDENT INNOVATION & SCIENTIFIC AFFAIRS, UCB

FLORENCE DAL DAGAN
CEO INNOVATION SOURCING DIRECTOR, NOVODORIK

GUY HÉLIN
CEO, SYNAGON

STEPHAN LENSKY
CHIEF OPERATING AND CHIEF BUSINESS OFFICE, ERMAB IOBIO THERAPEUTICS

SABRINA LESAGE
STRATEGIC ALLIANCE MANAGER, PIZZIERE

MARIE-ANGE N’ZOUTANI
DIRECTOR, EXTERNAL INNOVATION DRUG DISCOVERY, BUSINESS DEVELOPMENT & LICENSING, SANOIR

FRÉDÉRIC SCAIROLU
DIRECTOR, HEAD OF EXTERNAL INNOVATION EUROPE AND ASIA, IPSEN INNOVATION

NADINE WEISSLINGER-DARMON
MEDICAL DIRECTOR INNOVATION PRODUCTS, CLINICAL RESEARCH AND ACADEMIC ALLIANCES, GSK

ACADEMIA, TTOs

HARVE ANSANAY
OPERATIONS DIRECTOR, SATT AXIL

JÜRGEN BÄUER
DEPUTY MANAGING DIRECTOR, EMILEN TECHNOLOGY TRANSFER

GARALD BREIT
DIRECTOR, TECHNOLOGY BUSINESS DEVELOPMENT, CITY OF CHARLESTON

JEAN-LUC CHAGNOUD
HEALTHCARE BUSINESS DEVELOPMENT MANAGER, AQUITAINE SCIENCE TRANSFER

ANTHONY DACCACHE
BUSINESS DEVELOPER, SATT NORD

LILLA PARKAS
HEAD OF THE MANAGING DIRECTOR, RESEARCH COORDINATOR, MPI-CBG, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS

ESTHER LONGE
INDUSTRY LiASON MANAGER, ASCNOM

INVESTORS

FRANK HENSO
PRINCIPAL, HIGH-TECH GrüNDERSFONDS

JÉRÔME MAJOL
GENERAL MANAGER, FOUNDATION FOURNIER MAJOL

SARA NUNEZ-GARCIA
BIOTECH INVESTOR, FORMERLY PRINCIPAL WITH SOFINNOVA PARTNERS

ZHISHONG YAO
ASSOCIATE, CAPITAL PARTNERS, SOFINNOVA PARTNERS

LOFI YELLES CHAOUCHE
PARTNER, THEODORUS FUND

ASSOCIATIONS, CLUSTERS & LAW FIRMS

NICOLAS CARBONI
PROGRAM MANAGER, BESSAU C.U.R.I.E.

BARBARA FREISCHEM
MANAGEMENT DIRECTOR, EBI - EUROPEAN BIOPHARMACEUTICAL ENTERPRISES

YOHAN Grosjean
COMMUNICATION OFFICER, AFFSII - THE FRENCH ASSOCIATION OF OUTSOURCING AND INNOVATIVE COMPANIES

JEAN-LOUIS HUNAUT
PRESIDENT, SIMF - THE FRENCH ASSOCIATION OF THE ANIMAL HEALTH INDUSTRY

MARCO PINTORE
GENERAL MANAGER, BIOVALEU FRANCE

CHRISTIAN POLICARD
MEMBER OF THE BOARD, CHAIRMAN OF THE BUSINESS DEVELOPMENT SUB-COMMITTEE, FRANCE BIOTEC

ÉMILE ROYERE
GENERAL MANAGER, EURASANTE & NH CLUSTER

CÉCILE THÉARD-JALLU
PARTNER ATTORNEY, DE GAULLE FLEURANCE & ASSOCIES

ETIENNE Vervaecke
GENERAL MANAGER, EURASANTE & NH CLUSTER

TABLE OF CONTENTS

STEERING COMMITTEE ............................................................................................................. 4
ACADEMIA, TTOs ......................................................................................................................... 6
ASSOCIATIONS, CLUSTERS & LAW FIRMS ............................................................................. 8
INVESTORS ..................................................................................................................................... 9

BIOFIT AGENDA

HOSTED EVENTS AGENDA ........................................................................................................ 10

ONE-TO-ONE MEETINGS

Partnering - Who will you meet? ............................................................................................... 14
Would-be CEO ............................................................................................................................ 15

PITCH SESSIONS

Start-up Slams ............................................................................................................................. 16
Licensing Opportunity Presentations ............................................................................................ 20

CONFERENCES

PLENARY SESSION .................................................................................................................. 25

TRACK 1 | Best practices in academia-industry R&D collaborations ............................................. 26
TRACK 2 | Nurturing and licensing early-stage assets ........................................................................ 30
TRACK 3 | Early-stage innovation: Identify the right funding sources ............................................... 34

HOSTED EVENTS

Partnering Day - Boehringer Ingelheim .................................................................................... 38
Roche Day ...................................................................................................................................... 39
R&D Dating for Animal Health and Innovation ........................................................................... 40
Epid Symposium ............................................................................................................................. 41
SMMI-E/Yncréa Event .................................................................................................................... 42
IMODE ............................................................................................................................................ 43
EDCA - European Diagnostic Clusters Alliance ......................................................................... 44
PATHACOV ..................................................................................................................................... 45

EXHIBITION

Exhibitor List & Floor Plan .......................................................................................................... 46
Exhibitor Descriptions ................................................................................................................... 48

Organisers ....................................................................................................................................... 74
Supporters & Partners .................................................................................................................. 77
Sponsors ......................................................................................................................................... 80
At Ferring, we partner to deliver innovative medicines that changes people’s lives. As a global pharmaceutical company, we pursue strategic partnerships that leverage technologies and capabilities around the globe. In our approach to external innovation, we work as one connected unit with a commitment to establishing collaborations across the development continuum. Our goal is to create long-term mutually beneficial relationships.

We are focused on three therapeutic areas: Reproductive medicine & Women’s Health, Gastroenterology/Hepatology and Urology/Uro-oncology.

For more information please visit: www.ferring.com/en/collaborate-with-us
BAYER HEALTHCARE SAS
Website: www.bayer.fr
Bayer Pharmaceuticals located in Loos is one of the three divisions of Bayer Group in France. The pharmaceutical activities include: General Medicine (cardiology, women’s health), Specialized Medicine (hemophilia, oncology), Ophthalmology and Radiology. Bayer’s products help to address the increasing challenges of a growing and aging population and the resulting demand for innovative medicines. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. R&D expenses to EUR 4.5 billion. For more information: @Bayer_FR

BOEHRINGER INGELHEIM
Website: www.boehringer-ingelheim.de
Boehringer Ingelheim is a research-driven pharmaceutical company focused on improving the health and quality of life of patients in need. The company develops innovative therapies for which no satisfactory treatment options currently exist. As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

GENFIT
Website: www.genfit.com
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. It concentrates its efforts in areas of high unmet medical needs. Its lead proprietary drug candidate, elafibranor, is currently being evaluated in the Phase 3 study “RESOLVE-IT” in nonalcoholic steatohepatitis (NASH) as well as in a Phase 2 study in Primary Biliary Cholangitis (PBC).

MSD
Website: www.msd.com/licensing
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. With more than 100 significant business development transactions since 2016, our team has experience working on collaborations from discovery through clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

PFIZER
Website: www.pfizer.com
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. For more than 150 years, we have worked to make a difference for all who rely on us.

ROCHE
Website: www.roche.com
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines. In 2017, Roche invested CHF 10.4 billion in R&D.

VIB
Website: www.vib.be
VIB is a life sciences research institute, based in Flanders, Belgium. Some 1,500 top VIB scientists conduct pioneering basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications. These applications are often developed by young start-ups from VIB or through collaborations with other companies. This leads to additional employment and bridges the gap between scientific research and entrepreneurship.

LFB
Website: www.groupe-lfb.com
The LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare in three major fields of therapy: immunology, haemostasis and intensive care. The LFB Group is today a European key player in the field of therapeutic proteins. Over 2,000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients.

EBD GROUP
Website: www.ebdgroup.com
DAY ONE  
Tuesday, December 4th

8.30 am  
Conferences and roundtable discussions

9.30 am  
Name badge pickup & welcome coffee

ARTOIS 1  
Agnostic or pure players in the biotech sector: Who is becoming prominent in the early-stage financing rounds?

ARTOIS 2  
Artificial Intelligence to speed up drug discovery: The revolutionary road to advancing innovation

Therapeutics - CNS | Vaccines | Infectious Diseases

INNOV'AREA  
Licensing opportunity presentations

One-to-one meetings

11.00 am  
Networking break

1.00 pm  
Plenary session

PASTEUR AMPHITHEATRE  
Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?

2.30 pm  
Lunch

ARTOIS 1  
Beyond shared R&D means of pharma and academic institutions, common strategies for collective success

ARTOIS 2  
What are the recent initiatives to ensure more mature assets of academic origin?

Therapeutics - Cancer | Immunology

INNOV'AREA  
Start-up slams

3.30 pm  
Networking break

ARTOIS 1  
Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?

INNOV'AREA  
Licensing opportunity presentations

Therapeutics - Cancer | Diagnostics - Cancer

6.30 pm  
Bioparty

DAY TWO  
Wednesday, December 5th

8.30 am  
Conferences and roundtable discussions

9.30 am  
Welcome coffee

ARTOIS 1  
What roles do academic institutions or TTOs play as shareholders in spinoffs?

ARTOIS 2  
How can common pathways in human and animal health set up a new era for collaborations?

INNOV'AREA  
Start-up slams

One-to-one meetings

10.30 am  
Networking break

11.00 am  
Licensing opportunity presentations

Therapeutics | Research tools | Production tools

12.30 pm  
Lunch + would-be CEO networking lunch

ARTOIS 1  
Are immunotherapies still an investment Eldorado?

ARTOIS 2  
Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

INNOV'AREA  
Start-up slams

Bioproduction | Drug discovery tools | Diagnostics

3.30 pm  
Networking break

ARTOIS 1  
How available to biotech start-ups have philanthropic and other sources of soft funding become today?

ARTOIS 2  
Is externalising the tech transfer function for academic institutions a key to succeed?

INNOV'AREA  
Start-up slams

Bioproduction | Therapeutics - other indications

4.00 pm  
Networking break

ARTOIS 1  
Under pressure: How does the urge to bring rare disease therapies create a new range of business or collaborative models?

INNOV'AREA  
Awards ceremony

Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?

Therapeutics - Cancer | Diagnostics - Cancer

6.30 pm  
Bioparty

TRACK 1:  
Best practices in academia-industry R&D collaborations

TRACK 2:  
Nurturing and licensing early-stage assets

TRACK 3:  
Early-stage innovation: Identify the right funding sources
# AGENDA | HOSTED EVENTS

## Dec. 3rd

**ROOMS**
- Rotterdam: Boehringer Ingelheim Partnering Day
- Roermond: Hainaut Event
- Eurotop: Symposium
- Rembrandt: Convention
- Van Gogh: Roche Day

### Program
- **8.30 am**
  - WELCOME COFFEE
- **9.00 am**
  - Introduction
- **9.15 am**
  - Gut-Brain glucose signalling in the control of energy homeostasis
- **9.30 am**
  - Testing of New Drugs & Devices for Regulatory Approvals
- **10.00 am**
  - Food and type 2 diabetes: Restoring the Milieu Intérieur
- **10.30 am**
  - Insights from bariatric surgery
- **11.00 am**
  - Nanostructured materials: The next generation of active stents vessels
- **11.30 am**
  - Tissue Engineering approach
- **12.00 pm**
  - Regenerative medicine approach
- **12.30 pm**
  - Cardiovascular Disease, Restenosis and Thrombosis
- **1.00 pm**
  - Insights from bariatric surgery
- **1.30 pm**
  - Nanostructured materials: The next generation of active stents vessels

### Breaks
- **10.45 am**
- **11.45 am**
- **12.45 pm**

### Poster Session
- **1.15 pm**
- **2.15 pm**

### Lunch
- **12.30 pm**
- **2.00 pm**

### Networking Reception
- **5.30 pm**
- **6.30 pm**

### Awards
- **4.00 pm**
  - Best paper award
- **4:30 pm**
  - Conclusion & Invitation to the cheese and wine cocktail

## December 4th

### Program
- **9.00 am**
  - Introduction
- **9.30 am**
  - Testing of New Drugs & Devices for Regulatory Approvals
- **10.00 am**
  - Experience sharing of the Hauts-de-France’s institutions
- **10.30 am**
  - Introduction to the Interreg France-Wallonie-Vlaanderen programme
- **11.00 am**
  - PATHACOV project and patient impact
- **11.30 am**
  - Specific markers VOC (Volatile Organic Compounds)
- **12.00 pm**
  - Innovative tools for early diagnosis
- **12.30 pm**
  - Roundtable: “Organ on Chip for cell therapy and drug screening”
- **1.00 pm**
  - Presentation of the Yncréa Chair
- **1.30 pm**
  - Animal Health R&D Service Presentations
- **2.00 pm**
  - Award Ceremony of the AFVAC*

### Breaks
- **10.30 am**
- **11.00 am**
- **12.30 pm**
- **2.30 pm**

### Networking Reception
- **5.30 pm**
- **6.30 pm**

### Awards
- **4.00 pm**
  - Best paper award
- **4.30 pm**
  - Conclusion & Invitation to the cheese and wine cocktail

## December 5th

### Program
- **9.00 am**
  - Introduction to the Interreg France-Wallonie-Vlaanderen programme
- **9.30 am**
  - PATHACOV project and patient impact
- **10.00 am**
  - Specific markers VOC (Volatile Organic Compounds)
- **10.30 am**
  - Innovative tools for early diagnosis
- **11.00 am**
  - Roundtable: “Organ on Chip for cell therapy and drug screening”
- **11.30 am**
  - Animal Health R&D Service Presentations
- **12.00 pm**
  - Award Ceremony of the AFVAC*

### Breaks
- **10.30 am**
- **11.00 am**
- **12.30 pm**

### Networking Reception
- **5.30 pm**
- **6.30 pm**

### Awards
- **4.00 pm**
  - Best paper award
- **4.30 pm**
  - Conclusion & Invitation to the cheese and wine cocktail

*AFVAC: French Association of Veterinarians for Pets*
48 hours to meet your future project partners, obtain funding and accelerate innovation

**IDENTIFY**
- today’s innovative technologies, collaborations and licensing opportunities

**BENEFIT**
- from a wide range of attendees (Pharma - Biotech - TTOs - Academics - Investors)

**MEET**
- the most qualified players in the Life Sciences field

**DEVELOP**
- new collaborations and partnerships

**WHO WILL YOU MEET?**

- **30%** TTOs, Research institutions, Academics
- **20%** Pharma & Diagnostic companies
- **20%** Emerging Biotech companies
- **15%** Preclinical CROs and CDMOs
- **10%** Pre-seed, seed and Series A investors
- **5%** Professional services, consulting and law firms

**NEW WOULD-BE CEO**

December 5th, 2018 | 12.30 - 2.00 pm | Exhibition Hall

Are you a bioentrepreneur seeking a project? Or do you have projects seeking a CEO?

BioFIT is pleased to announce the organisation of a “Would-be CEO Networking Lunch” on the 2nd day of BioFIT (December 5th).

As talented CEOs are frequently sought-after by many stakeholders of the biotech industry, to both launch and drive new companies to success, this “Would-be CEO Networking Lunch” will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this important issue.

Please note that would-be CEOs can also be identified through the BioFIT partnering platform.

Any bioentrepreneur looking for a project to get involved in is welcome to join BioFIT and particularly this “Would-be CEO Networking Lunch”. Any incubator or tech transfer entity looking for an entrepreneur to lead their start-up launch projects is also welcome to join.
The Start-up Slams are presented by bioentrepreneurs of innovative start-up companies (from creation up to Series A). During the presentations, the selected candidates will present their project to potential partners and investors who can support their company and receive valuable feedback and advice («speed-mentoring») from a jury of experts.

The most innovative start-ups will be awarded on BioFIT 2nd day at 3.30 pm in the INNOV’ AREA in the exhibition hall.

AWARD CEREMONY Dec. 5th 3.30 pm | INNOV’ AREA EXHIBITION HALL

Discovered the most innovative start-ups in the following fields:

- Therapeutics - Cancer | Immunology
  - OncoQR ML GmbH
  - Peptomycs S.L.
  - Odimma
  - OPSYON
  - LIFT Biosciences
  - Tubulis

- Delivery | Discovery | Research Tools
  - MyLife Technologies
  - ATLANTRAM
  - Mind the Byte
  - InBrain Pharma

- Production Tools
  - NUMAferm
  - UGIsense

- Diagnostics
  - Carmentix
  - Sencet

- Therapeutics - Other Indications
  - Op2Lysis
  - Phyteau
  - APIQS
  - Madam Therapeutics
  - MTact
  - Elasmogen Ltd

Juries’ Experts:

- Garold Breit
  Director, Technology Business Development, City of Charleston

- Florence Dal Degan
  R&D Innovation Sourcing Director, Novo Nordisk

- Gustavo De Freitas Morais
  Partner, Dannemann, Siemens, Bigler & I Moreira

- Yanxiang Zhou
  Associate, Illumina Ventures

- Jerôme Majoiré
  General Manager, Fournier-Majorie Foundation

- Ward Capoen
  Senior Analyst, V-Bio Ventures

- Esther Lange
  Industry Liaison Manager, Ascension

- Stephan Lensky
  Chief Operating & Chief Business Office, Erimab Biotherapeutics

- Jürgen Bauer
  Deputy Managing Director, Emblem Technology Transfer

- Marie-Ange N’Zoutani
  Director, External Innovation Drug Discovery, Business Development & Licensing, Sanofi

- Philippe Monteyne
  Partner, Fund+

- Alison Munro
  Alison Munro Corporate Language

- Yanxiang Zhou
  PharM. D, Analyst, Turenne Capital

- Mehdi Aïnouche
  PharM. D, Analyst, Turenne Capital

- Sergé Pampfer
  Managing Director, WBC Incubator

- Jürgen May
  Global Business Development Manager Roche

- Frank Hensel
  Principal, High-Tech Gründerfonds

- Ward Capoen
  Senior Analyst, V-Bio Ventures
### AGENDA | START-UP SLAMS

**Dec. 4th 2.30 > 4.00 pm | INNOV’ AREA**

#### THERAPEUTICS - CANCER | IMMUNO-ONCOLOGY

<table>
<thead>
<tr>
<th>Company</th>
<th>Fields</th>
</tr>
</thead>
<tbody>
<tr>
<td>OncoQR ML GmbH</td>
<td>Immuno-oncology</td>
</tr>
<tr>
<td>Peptomyc S.L.</td>
<td>Cancer therapy</td>
</tr>
<tr>
<td>Odimma</td>
<td>Personalised Medicine</td>
</tr>
<tr>
<td>OPSYON</td>
<td>Immune checkpoint</td>
</tr>
<tr>
<td>Lift BioSciences</td>
<td>Cancer</td>
</tr>
<tr>
<td>Tubulis</td>
<td>Antibody Drug Conjugates (ADCs)</td>
</tr>
</tbody>
</table>

**Dec. 5th 9.00 > 10.30 am | INNOV’ AREA**

#### DELIVERY | DISCOVERY | RESEARCH TOOLS

<table>
<thead>
<tr>
<th>Company</th>
<th>Fields</th>
</tr>
</thead>
<tbody>
<tr>
<td>MyLife Technologies</td>
<td>Microneedles</td>
</tr>
<tr>
<td>ATLANGRAM</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Mind the Byte</td>
<td>Drug Discovery</td>
</tr>
<tr>
<td>InBrain Pharma</td>
<td>Brain Infusion</td>
</tr>
</tbody>
</table>

**Dec. 5th 2.00 > 3.30 pm | INNOV’ AREA**

#### PRODUCTION TOOLS

<table>
<thead>
<tr>
<th>Company</th>
<th>Fields</th>
</tr>
</thead>
<tbody>
<tr>
<td>NUMAFERM</td>
<td>Recombinant</td>
</tr>
<tr>
<td>UGISense AG</td>
<td>Ugrimers</td>
</tr>
</tbody>
</table>

**Dec. 5th 9.00 > 10.30 am | INNOV’ AREA**

#### DIAGNOSTICS

<table>
<thead>
<tr>
<th>Company</th>
<th>Fields</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carmentix</td>
<td>Diagnostics</td>
</tr>
<tr>
<td>Sencet</td>
<td>Cancer diagnostics</td>
</tr>
</tbody>
</table>

#### THERAPEUTICS - OTHER INDICATIONS

<table>
<thead>
<tr>
<th>Company</th>
<th>Fields</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phyteau</td>
<td>Diabetes</td>
</tr>
<tr>
<td>APiOS</td>
<td>Bone reconstruction</td>
</tr>
<tr>
<td>Madam Therapeutics</td>
<td>Anti-infectives</td>
</tr>
<tr>
<td>MTact</td>
<td>Tauopathies</td>
</tr>
<tr>
<td>Op2Lysis</td>
<td>Intracerebral Hemorrhage (ICH)</td>
</tr>
<tr>
<td>Elasmogen Ltd</td>
<td>SoloMERs</td>
</tr>
</tbody>
</table>
LICENSING OPPORTUNITY PRESENTATIONS

The Licensing Opportunity Presentations are presented by TTOs, universities or related structures which have ready-to-be-licensed technologies. The aim of this session is to foster alliances and business development opportunities on innovative projects stemming from academia.

DISCOVER THE LASTEST INNOVATIONS IN THE FOLLOWING FIELDS:
THERAPEUTICS - CANCER
- IRICoR
- University of Bradford
- National Cancer Institute
  - RAF inhibitor | RAS-mutant cancers | Paradoxical activation
  - Cancer | Therapeutics | Peptide
  - Cancer | Tumor-specific | Antibody

DIAGNOSTICS - CANCER
- University of Bradford
- Luris
- University of Pardubice
  - Cancer | Diagnostic | Metastasis
  - Cancer predisposition | Lynch syndrome / colorectal cancer | Genetic variants
  - Cancer diagnostic | Mass spectrometry | Lipid

BIOPRODUCTION
- University of Pardubice
  - Protein purification | Phosphopeptides enrichment | TiO2 nanotubes

DRUG DISCOVERY TOOLS
- SATT AxLR
- Ghent University
  - Electrosynned nanofibers culture system | Haptokinesis | Drug screening
  - Poly(2-oxazoline)s | Polymer therapeutics | Drug delivery

DIAGNOSTICS
- Linksum
  - ZEBRA biomarker | Serological test | Post-transplant lymphoproliferative disorder (PTLD)
BioFIT 2018 conference programme is tailored to fit the expectations of its audience, whose sharp minds evolve in the fast-paced and dynamic Life Sciences sector. Built around 12 sessions and 1 plenary session, the 2018 programme is rooted in three custom-made tracks, addressing the right funding sources for early-stage innovation, best practices in academia-industry R&D collaborations, and nurturing early-stage assets.

**TRACK 1**

**Best practices in academia-industry R&D collaborations**

**TRACK 2**

**Nurturing and licensing early-stage assets**

**TRACK 3**

**Early-stage innovation: Identify the right funding sources**

**PLENARY SESSION**

DEC. 4TH 11.30 AM - 1.00 PM  Pasteur Amphitheatre

**SEED FUNDS CROSSING BORDERS: HOW FAR AND HOW FAST IS THE EARLY-STAGE INVESTMENT MARKET IN BIOTECH GLOBALISING?**

The early-stage investment actors can be seen as traditionally geographically anchored, but now seed and Series A investors tend to invest in more diverse geographic areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more willing to take risks, will it change the risk landscape? Isn’t there an ill-balance today between the geographical origin of investment capabilities and the areas that are crawling with projects needing equity investment?

**MODERATOR:**
Lisa Urquhart
Editor, EP Vantage

Zishan Haroon
Chairman and General Partner, Julz Co

Mirko Scherer
Managing Partner and CEO, TVM Capital China Limited

Jemila Houacine
Associate, Medicxi

Stephan Lensky
Chief Operating and Chief Business Officer, EpimAb Biotherapeutics
Beyond shared R&D means of pharma and academic institutions, common strategies for collective success

Beyond sharing physical means, this session focuses on deliberate strategies of life sciences industry and the academic world to pool R&D resources to address common questions and reach common goals through shared R&D strategies and aligned incentives. We will review some partnerships that have chosen to take a leap forward and collaborate on scientific projects that they couldn’t do on their own.

MODERATOR:
Ewa G. Truchanowicz
Life Sciences Lead, University of Birmingham Enterprise

Thierry Guillaudeux
Director, UMS Biosit SFR

Marco A. Chacón
AVP Industry Alliances, University of Maryland, Baltimore

Dominic De Groote
Sr. Business Manager Pharma, Ghent University

Nick Clarke
Head of UK Academic Partnerships, External Sciences and Innovation, Pfizer Worldwide Research and Development

Artos 1 Room

Artos 2 Room

Artificial intelligence to speed up drug discovery: The revolutionary road to advancing innovation

Companies are now using machine learning in highly specific ways to streamline and improve many day-to-day biomedical research tasks. The use of AI has shifted from generalist tasks to purpose-built tools with numerous applications to speed up drug discovery at all the different research stages. The panel will address some of the uses of AI, ultimately potentially cutting R&D costs by aggregating and synthesising information, repurposing existing drugs, generating and validating novel drug candidates, designing drugs and preclinical experiments, etc.

MODERATOR:
Melanie Senior
Healthcare Writer & Analyst, Pharma Intelligence | Informa

Phil L’Huillier
Head, European Innovation Hub, MSD

Avishai Levy
CEO, MIGAL - Galilee Research Institute

Emmet Browne
CEO, Nuritas

Pascal Sempé
Cognitive/AI Solution Specialist - Life Sciences, IBM Watson Health Solutions, IBM

DEC. 4TH 2.30 - 4.00 PM

DEC. 4TH 9.30 - 11.00 AM
HOW CAN COMMON PATHWAYS IN HUMAN AND ANIMAL HEALTH SET UP A NEW ERA FOR COLLABORATIONS?

Why should a human-focused biotech company be interested in the animal health industry? Are there common grounds that can lead to more frequent and fruitful collaborations between animal and human health companies in the future? Today, it is obvious that the animal health industry offers a clear value proposition to human biotechnology companies, which can maximise the financial and clinical impact of their assets by leveraging both human and veterinary health. The physio pathological features of several diseases (cancer, osteoarticular affections, infectious diseases, pain…) are progressively understood as at least common between animal and human. This paves the way to innovative products developed under the sign of a so-called comparative medicine. This panel will encourage a provocative, straightforward and realistic discussion on what each side needs from the other to set up mutual beneficial partnerships.

PATIENT ORGANISATIONS TO JOIN THE PHARMA-BIOTECH-ACADEMIA TRIO: IS A FOURTH MUSKETEER CALLING FOR A NEW WAY TO MANAGE ALLIANCES?

What are the consequences and benefits of adding patient organisations to existing alliances? How do these collaborations work? How do they create value for the whole life sciences community? What is the actual influence on patients of public/private partnerships? What is the actual involvement of patient organisation in financing the collaborations?

At Boehringer Ingelheim we believe in forming durable partnerships to develop innovative new medicines in areas of high unmet need. Our relationships range from discovery research, development and technology collaborations to clinical and commercial partnerships and full-scale, long-term strategic alliances.

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

We invite you to find out more about partnering with us by visiting www.boehringer-ingelheim.com/partnering

Visit the Pfizer partnering website to learn more about:

• Our Areas of Interest
• Our Process
• Partnering Highlights

• Our Partnering Leadership
• Contact Information
WHAT ARE THE RECENT INITIATIVES TO ENSURE MORE MATURE ASSETS OF ACADEMIC ORIGIN?

What are the latest group actions to have been jointly taken by the industry, academic institutions, equity investors, and governmental bodies that take academic-origin assets as early as possible and inject the proper amount of money into them, in order to get the project licensed at the right moment and at the safest possible stage?

MODERATOR:
Ian Carter
Director,
Carter Research Navigation

Steven J. Klein
VP Business Development,
IRICoR - Institute for Research in Immunology and Cancer - Commercialization of Research

Michael L. Salgaller
Supervisor, Invention Development and Marketing Unit, National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center

Hélène Peyro-Saint-Paul
Partner and Cofounder, LallianSe Entrepreneurs

WHAT ROLES DO ACADEMIC INSTITUTIONS OR TTOS PLAY AS SHAREHOLDERS IN SPINOFFS?

When spinning out a company, one strategy applied by the university or TTO is often to take an equity position in the start-up. When this happens, how do the university or TTO play their role as a shareholder? Do they keep a close eye on the development of the company and continue to offer active support or do they act more as a sleeping partner? How is the risk measured and what is the exit short-term/long-term strategy chosen by those unusual shareholders?

MODERATOR:
Einat Zisman
Independent Consultant

Pascale Augé
Chairman of the Executive Management Board, Inserm Transfert

Caroline Barelle
CEO, Elasmogen

Grégoire Franoux
Global Head of Business Development and Licensing, Oxurion

Adrian Ibrahim
Head of Business Development and Technology Transfer, Wellcome Sanger Institute
IS EXTERNALISING THE TECH TRANSFER FUNCTION FOR ACADEMIC INSTITUTIONS A KEY TO SUCCEED?

Technology transfer offices play a central role in the biotech ecosystem, as they are meant to bridge the gap between bench and bedside and succeed in commercialising an academic discovery. As most new biotech start-ups arise out of IP resulting from academic research, the efficiency of this system is of outmost importance. This panel discussion will highlight both successes and limits in that externalisation of tech transfer approach.

MODERATOR:
Rafaela Kunz
Open Innovation Consultant, INSEA Consulting

Alain Chevallier
Life Sciences Partner, Truffle Capital

Gábor M. Lamm
Managing Director, EMBLEM Technology Transfer

Wim Van Camp
General Manager Technology Transfer, Ghent University

Lionel Pujol
Operational Support Director, SATT Nord

DEC. 5TH 4.00 - 5.30 PM
Artois 1 Room

UNDER PRESSURE: HOW DOES THE URGE TO BRING RARE DISEASE THERAPIES CREATE A NEW RANGE OF BUSINESS OR COLLABORATIVE MODELS?

Bringing new therapies to treat rare diseases requires more than scientific innovation. Innovation in business models and incubation financing is critical as the need to find ways to cost effectively develop new medication is becoming highly important. Initiatives like collaboration centres and rare disease centres try to take the best of both worlds by implementing multidimensional approaches to address the needs of the rare disease community. In addition to conducting their own research, collaborative models that feature pharmaceutical companies, academic institutions, start-ups and patient groups are now being put in place.

MODERATOR:
Alastair Kent
Independent Healthcare Consultant

Tiina K. Urv
Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (NIH)

Anjan Aralihalli
Venture Partner, CTI Life Sciences Fund II

Bertrand Verwee
International Health Policy Leader, Rare Diseases Roche

Nawal Bahia El Idriessi
Business Developer, Catalyze

EBD Group’s mission is to help collaborations get started in the life science sector. Our partnering conferences are the largest and most productive conference platform in the industry, with landmark events powered by our state-of-the-art partnering software, partneringONE®. Delegates efficiently identify new opportunities and engage via one-to-one meetings. Annually our events attract 15,000 senior executives who engage in 50,000 partnering meetings, driving innovation in our industry. www.ebdgroup.com

VIB is open for partnering and collaboration

VIB is an excellence-based entrepreneurial academic institute that focuses on translating basic scientific results into pharmaceutical, industrial and agricultural applications.

www.vib.be

science meets business
When creating a biotech start-up, different routes can be taken: the virtual biotech model, the technology platform model, the one single asset company... How do those initial choices influence the exit scenario of the company?

**Conference Programme**

**Early-stage innovation: Identify the right funding sources**

**DEC. 4th 9.30 - 11.00 AM**  
**Artois 1 Room**

**AGNOSTIC OR PURE PLAYERS IN THE BIOTECH SECTOR: WHO IS BECOMING PROMINENT IN THE EARLY-STAGE FINANCING ROUNDS?**

The seed investment market is comprised of players with a varied degrees of specialisation, from totally agnostic players involved in multiple industries, to pure players focusing on specific therapeutic areas. Do most specialised funds attract the more generalist types in the financing rounds? What is the importance of the amount of seed investment today for cross-industry funds, 100% healthcare-oriented funds and pure players in the biotech industry, respectively?

Jan Adams  
Managing Director,  
EMBL Ventures

Jean-Charles Brosse  
Partner Healthcare and Life Sciences,  
Positive Capital

Jacky Vonderscher  
CEO,  
ENYO Pharma

Jonathan Tabin  
Investment Director,  
Arix Bioscience

Camilla Petrycer Hansen  
Senior Associate,  
Novo Seeds

**MODERATOR:**  
Lucie Ellis  
Managing Editor,  
In Vivo Pharma Intelligence | Informa

**DEC. 4TH 4.30 - 6.00 PM**  
**Artois 1 Room**

**THINKING OF THE EXIT SCENARIO TO SHAPE A BIOTECH START-UP AT ITS FIRST STEPS: WHICH MODEL FOR WHICH TERM OF EXIT?**

When creating a biotech start-up, different routes can be taken: the virtual biotech model, the technology platform model, the one single asset company... How do those initial choices influence the exit scenario of the company?

Peter Leonardi  
CEO,  
OmniCyte

Mark Krul  
Partner,  
Aglaia BioMedical Ventures

Rodolphe Besserve  
Head SuFT Advisory,  
Société Générale Corporate Investments and Banking

**George Hoffmann**  
Co-founder and CEO,  
Network Immunology
ARE IMMUNOTHERAPIES STILL AN INVESTMENT ELDORADO?

Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth potential after several years of being an investment blockbuster? What have been the 2018 investment successes in immunotherapy? Will immunotherapy disrupt the oncology market? Are we at the growth, maturity, or saturation stage when we talk about investing in immunotherapy?

HOW AVAILABLE TO BIOTECH START-UPS HAVE PHILANTHROPIC AND OTHER SOURCES OF SOFT FUNDING BECOME TODAY?

All of these non-dilutive financing sources are becoming increasingly numerous thanks to both the emergence of interest expressed by many trusts and foundations in financing innovative start-ups, and also to the many governmental schemes that are devoted to financing the first steps of biotech start-ups. How do these sources of revenue lead to real leverage effect or create constraints for the companies? What types of constraints do they expose biotech entrepreneurs to?

MODERATOR:
Chris Shelley
Partner and Head of Life Sciences, Penningtons Manches LLP

Bram Vanparys
Partner, Gimv

Madiha Derouazi
Founder and CEO, AMAL Therapeutics

Michael Motz
Chief Business Officer, NETRIS Pharma

Juan R. Garcia
CEO, BioSeed Capital

Fatima Sulaiman
Head of Research and Services, Scleroderma & Raynaud’s UK

Steve Poirier
CEO and Co-founder, MONOGENIC Pharmaceuticals

Maya Merrell
Director, Business and Partnership Development, Fast Forward

Oliver Gajda
Executive Director and Founder, European Crowdfunding Network

MODERATOR:
Arezki Yaïche
Financial Journalist, Paris Bureau Chief - Mergermarket

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases, where there is still considerable unmet need. Elafibranor, its lead compound, is currently evaluated in a Phase 3 study in NASH and in a Phase 2 study in PBC.
Fostering Innovation
Boehringer Ingelheim knows what it takes to be innovative and entrepreneurial. From the small factory in 1885 to today’s global pharmaceutical organisation, we know how important it is to nurture and develop emerging science and technology. Our track record of bringing breakthrough medicines to patients starts with new ideas and new science, and collaborations with external partners play a key role in helping us deliver an innovation-led portfolio. Join us at our partnering day to explore how we can develop the next generation of medicines together.
For more information on our partnering interests please visit: www.boehringer-ingelheim.com/partnering/interests

Meet our Research and Partnering Teams
12.00 - 1.30 PM Networking Lunch
12.30 - 3.30 PM 1:1 Partnering Meetings
3.45 - 4.30 PM Company Presentations
4.30 - 5.30 PM Panel Discussion: Collaborative Research and Partnering with Boehringer Ingelheim
5.30 - 6.30 PM Networking Reception

Programme Dec. 4th, 2018 | 9.00 am - 6.00 pm Van Gogh Room

“HEALTH INNOVATION IN THE HAUTS-DE-FRANCE REGION”

9.00 - 9.30 AM | Welcome coffee
9.30 - 9.50 AM | Introduction
9.50 - 11.00 AM | Experience sharing of the Hauts-de-France’s institutions
• Stroke management through telemedicine, set up by the Hospital Centre of Valenciennes
• The Patient Report Outcomes (PROs) and the anticipation of the chemotherapy “okay” for a connected application
• POSOS: Artificial intelligence in the service of prescription for medication
• Wound management through a digital solution
• The importance of focusing on humans and staying connected to fight cancer: Children’s words, a family issue
• Learning through simulation and surgical robotics for therapeutic innovation

11.00 - 11.20 AM | Break

11.20 AM - 12.10 PM | Turning the spotlight on start-ups
12.10 - 1.00 PM | Connected Medicine
• Which e-health device could improve patient management?
• My Oscar: The patient who carries is own hospital file
• Competence sharing in diabetology: PreciDIAB, the project of Lille
• Innovation in radiology: The Hauts-de-France regional project in neuroradiology

1.00 - 2.15 PM | Lunch
2.15 - 3.15 PM | Big data
• What are the vision and the strategy for IBM Watson Health in the healthcare sector?
• The INCLUDE project: Data warehouse and artificial intelligence at the Ille University Hospital

3.15 - 4.15 PM | Access and funding for innovation
• The Region’s vision
• Personalised reimbursement model (PRM)
• How to maintain the access to therapeutic innovation?

4.15 - 4.30 PM | Break

4.30 - 5.30 PM | Right and ethics
• Roundtable discussion on digital health: Educational, ethics and legal aspects

5.30 - 6.00 PM | Key learning points | Conclusion
BioFIT 2018 hosts the 4th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal healthcare industry (SIMV)’s initiative. Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourages investments and leads to therapeutic innovation.

Programme Overview

8.30 - 9.00 AM WELCOME COFFEE & SYMPOSIUM MATERIAL DISTRIBUTION
9.00 - 9.15 AM INTRODUCTION AND WELCOMING
9.15 - 10.00 AM Gut-Brain glucose signalling in the control of energy homeostasis
Gilles Mithieux, Director UMR-S1 2 1 3-UCBL, Director of ALECS, Inserm 1 2 1 3, Faculty of Medicine Laennec
10.00 - 10.45 AM Food and type 2 diabetes: Restoring the Milieu Interieur
Roy Taylor, Professor of Medicine and Metabolism and Director, Newcastle Magnetic Resonance Centre, Newcastle University
10.45 - 11.30 AM Microbiota and Cardiometabolic disease
Albert K. Groen, Professor of surgery, University of Lille, CHU Lille Inserm
11.30 AM - 2.30 PM DRINK + POSTER SESSION + LUNCH
2.30 - 3.15 PM Incretins, diabetes and CV disease
Nikolaus Marx, Professor of Medicine / Cardiology, Head of the Department of Internal Medicine I, University Hospital Aachen
3.15 - 4.00 PM Therapeutic potential of multi-incretin therapy — from mice to men
Aimo Kannt, Head, Comorbidities and Complications of Diabetes, Sanofi Diabetes Research
4.00 - 4.30 PM NETWORKING BREAK
4.30 - 5.00 PM BEST PAPER AWARD
5.00 PM CONCLUSION & INVITATION TO THE CHEESE AND WINE COCKTAIL

Organised by: simv.org
Contact: secretariat@simv.org

In partnership with: egid.fr
IMODE is organising its second annual convention during BioFIT with a morning of conferences and participation in the BioFIT one-to-one meetings during the afternoon.

Conference Programme Overview:

8.30 - 9.15 AM  
Name badge pickup and Welcome coffee - BioFIT

9.15 - 9.30 AM  
IMODE overall presentation  
Pr. Frédéric Affouard, University of Lille, UMET Laboratory, IMODE’s coordinator

9.30 - 10.00 AM  
Testing of New Drugs & Devices for Regulatory Approvals  
Dr. Isaac John, Ashford and St Peter’s Hospital’s NHS Foundation Trust

10.00 - 10.30 AM  
Electrospinning approach for drug delivery  
Dr. Stéphanie Degoutin, University of Lille, UMET Laboratory

10.30 - 11.00 AM  
Nanostructured materials: The next generation of active stents vessels  
Dr. Ariane Boudier, University of Lorraine, Director of CITHEFOR Laboratory

11.00 - 11.30 AM  
Networking break - BioFIT

11.30 AM - 12.00 PM  
Tissue Engineering approach  
Dr. Nicolas L’Heureux, University of Bordeaux, Director of BioTis Laboratory

12.00 - 12.30 PM  
Regenerative medicine approach  
Dr. Laurence Bordenave, CHU Bordeaux, Head of Nuclear Medicine

12.30 - 1.00 PM  
Cardiovascular Disease, Restenosis and Thrombosis  
Dr. Blondine Maurel, CHU Nantes, Vascular surgeon

1.00 - 2.30 PM  
Lunch - BioFIT

2.30 - 6.30 PM  
One-to-one meetings - BioFIT

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF). The project's overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

Project partners:

project-imoide.eu
EDCA invites you to a round table to exchange on the contribution of AI to next-generation diagnostics.

About EDCA:
European Diagnostic Clusters Alliance – EDCA is the first European network serving the competitiveness of the medical diagnostic industry. It federates 8 European clusters and counts 350 companies.

The purpose of EDCA is:
• To promote competitiveness of European industry in the area of medical diagnosis. The association will enhance the synergies between academic research, clinical research, health authorities and diagnostic companies;
• To ease the growth of European SMEs in medical diagnostic;
• To promote the development of diagnostic clusters and competitiveness clusters in Europe;
• To promote cooperation between diagnostic clusters (inter-cluster) in order to help build European collaborative projects.

EDCA members:

Head of Project: Pr. Régis Matran, Professor of Respiratory Physiology, Lille University Hospital

Early diagnosis of human diseases through analysis of VOC in exhaled breath
The challenge is to develop and implement an innovative methodology in the health field and in particular in the early diagnosis of bronchopulmonary cancers.

The project will enable all populations on both sides of the border, regardless of socio-economic level, to have access to a simple, non-traumatic method for early detection of bronchopulmonary cancer and other human diseases.

Programme Overview:

9.00 - 9.30 AM  Name badge pickup and Welcome coffee – BioFIT
9.30 - 10.30 AM  Introduction to the Interreg France-Wallonia-Vlaanderen Programme Pathacov Project and patient impact
10.30 - 11.00 AM  Networking break – BioFIT
11.00 AM - 1.00 PM  Specific markers VOC (Volatile Organic Compounds) Innovative tools for early diagnosis
1.00 - 2.00 PM  Lunch – BioFIT

Project partners:

With the support of the European Regional Development Fund
ALCAMI CORPORATION
Website: www.alcaminow.com
With seven sites across the globe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services. To meet client needs around the world, Alcami fields state-of-the-art facilities at strategic locations in the United States and European Union.

ALIRA HEALTH
Website: www.alirahealth.com
Alira Health is an international advisory firm providing integrated Transaction Services, Strategy and Medical Affairs consulting and contract research to companies in the Life Science industries. We partner with clients to identify the best roadmap for advancement and goal realization. We provide the right financial, scientific, clinical and marketing tools to empower their ideas, implement their strategies and succeed at every turn.

AMYLGEN
Website: www.amylgen.com
Amylgen is a preclinical CRO offering in vivo models of psychiatric and neurodegenerative diseases. By combining a strong experience in behavior with expertise in biochemistry, neurochemistry and histology, Amylgen offers an integrated service. Your product can be evaluated on multiple aspects of brain function including memory, depression, anxiety. All behavior effects may be supported by relevant analysis helping the understanding of the mechanism of action on brain health.

A&M LABORATORY GROUP
Website: www.am-labor.de
Situated in the Heart of Europe the A&M Laboratory Group offers GxP compliant analytical services «Made in Germany». With 200+ dedicated scientists and technicians, state-of-the-art equipment and a 25+ year flawless track record in authority and client audits, A&M is your analytical one-stop shop, supporting the development of your drug from development to manufacturing. With clients ranging from single person start-ups to big pharma we could be the ideal partner for your outsourcing needs, too.

AEPODIA
Website: www.aepodia.com
Aepodia is a solution provider specialised in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Aepodia offers expertise and innovative approaches to optimise the clinical development programmes of products as well as the management and operational execution of clinical studies carried out in multiple countries. With offices in Belgium and France, Aepodia is a recognised partner for pharmaceutical and biotechnology companies.

ANTINEO
Website: www.antineo.fr
Antineo accompanies clients in the preclinical development of novel anticancer agents. We provide strategic advice for preclinical development (choice of indications to focus on etc.), and expertise and in vitro, ex vivo and in vivo services aiming at characterising the mode of action and the anti-tumoral efficacy of new drugs. We have a strong expertise in immunotherapies, and in the development and characterisation of original models for secondary resistances to gold standards.

3DNEUROSECURE
Website: www.3dneurosecure.com
Multimodal bioinformatics more accessible to biologists, computer scientists, innovators and everyone in between.
AxLR is a technology transfer acceleration company. Our specialty is helping innovative projects derived from academic research reach maturity and commercialization. We work with the main public-sector research laboratories in France’s Mediterranean area in Occitanie, one of the most dynamic locations in Europe, with over 200 laboratories and some 12,000 researchers.

Baccinex is a Swiss based fill&finish CDMO specialized in development and manufacturing of sterile & lyophilized clinical material for pre-clinical, Phase I, II and III as well as commercial supply batches. Our expertise is forged by 15 years of sterile clinical and commercial material manufacturing. We are a one-stop flexible structure CDMO with a batch size from 500 to 12'000 vials on one production line. We also propose in-house sterile ampoules manufacturing.

The «Association Française des Sociétés de Services et d’Innovation (AFSSI)», French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners. AFSSI represents over 130 companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs.

Baccinex is a Swiss based fill&finish CDMO specialized in development and manufacturing of sterile & lyophilized clinical material for pre-clinical, Phase I, II and III as well as commercial supply batches. Our expertise is forged by 15 years of sterile clinical and commercial material manufacturing. We are a one-stop flexible structure CDMO with a batch size from 500 to 12'000 vials on one production line. We also propose in-house sterile ampoules manufacturing.

The «Association Française des Sociétés de Services et d’Innovation (AFSSI)», French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners. AFSSI represents over 130 companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs.

Aquitaine Science Transfer is the Technology Transfer Office for the south west of France, covering 5500 researchers and 135 laboratories. We represent the regional academic research labs: Bordeaux University, INSERM, CNRS, Pau University, Bordeaux Polytechnic Institute... Since our creation in July 2012, we have signed 48 license agreements, patented 285 technologies and created 17 startups. Health, wellness and medical devices represent a key business in which our company is highly involved.

Atlanpole Biotherapies is a competitiveness cluster involved in the medicine of tomorrow. It is focused for the development of new therapies, immunotherapy, regenerative medicine and radiopharmaceuticals, on the bio-medicine value chain from target discovery to clinical evaluation, completed by digital and nutrition approach. The projects of our network of 233 members, both academic and industrial, show the excellence of our expertise in personalized medicine.
CONSORTIUM FINDMED
Website: www.findmed.fr
FINMDMED is a consortium of French academic Carnot institutes devoted to human and animal Health. Covering the whole R&D value chain, its role is to support Small Medium-sized Enterprises development by facilitating access to academic research and technological resources. It gathers 7 leading institutes in Health (Vision institute, Institut Pasteur, Institut Curie, ICM, INRA, CALYM, Imagine) and 5 more in chemistry, formulation and digital (Chimie Balard Cirimat, I2C, M.I.N.E.S, Smiles, TN@UPSaclay).

CZECHINVEST
Website: www.czechinvest.org
CzechInvest, the investment and business development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages overseas companies to look at the Czech Republic as their partner of choice. The agency helps its Czech and international customers by providing services that range from information provision and consultancy to implementation of business development programmes.

BLUEREG PHARMA CONSULTING
Website: www.bluereg-group.com
BlueReg – Your regulatory partner to Europe and beyond
BlueReg is a consulting company offering strategic regulatory advice to life sciences companies. We provide flexible solutions or operational platforms to meet your company’s needs from product development, registration through to launch & product maintenance activities.
Our internal experts are committed to support biotech and pharma companies with the best scientific & regulatory advice to transform innovation into a successful product.

CILOA SAS
Website: www.ciloa.fr
Ciloa is an exosome-based R&D powerhouse that customize exosomes to contain any chosen proteins embedded in their membrane & inside their cytosol. Exosomes are naturally tailored in vivo by cells and membrane proteins complexes are sorted with their fully native conformation.
Natural properties of exosomes combined with Ciloa disruptive technology allow to develop I) antibodies against challenging targets, II) exosome-based therapeutic vectors, III) virus & adjuvant free vaccines.

CARAKTERS
Website: www.carakters.com
Carakters is a boutique innovation-focused law firm based in Paris. By using original methods (results chart, risks mapping), Carakters works as project manager for life sciences actors leading innovative projects in drug discovery, connected devices and biotechnologies, with a focus on public-private consortia, industry-academia collaborations and technology transfers. Carakters also acts as R&D contract manager and offers its clients risks assessing tools to protect their confidential assets.

DIVERCHIM CDMO
Website: www.diverchim.com
DIVERCHIM CDMO is a dedicated manufacturer of Active Pharmaceutical Ingredients required in small quantities (From tens of grams up to hundreds of kilograms). Based on its expertise in terms of chemical synthesis as well as documentation and regulatory aspects for commercial API manufacture, DIVERCHIM has developed over the last years its offer for pre-clinical and clinical needs for biotech and pharma companies.

CITOXLAB
Website: www.citoxlab.com
With nine facilities located in France, Canada, the US, Denmark and Hungary, Citoxlab offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies. Citoxlab carries out studies in general and reproductive toxicology, immunology, pharmacology and preclinical and clinical bioanalysis/biomarkers. With Solvo joining the Group, products and services in the field of transporters and DDI are now available.

CZECHINVEST
Website: www.czechinvest.org
CzechInvest, the investment and business development agency of the Ministry of Industry and Trade, works with businesses based in the Czech Republic to support their development and encourages overseas companies to look at the Czech Republic as their partner of choice. The agency helps its Czech and international customers by providing services that range from information provision and consultancy to implementation of business development programmes.

DERMA
Website: www.dermaneurope.com
The Interreg 2 Seas project DERMA aims to develop new interventions for the management and treatment of dermal ulcers and related skin conditions. By addressing market and patient need, the project will deliver advanced technologies ready for exploitation by industry to manufacture improved products for the treatment of patients. The objectives are to design, develop and evaluate an odour-absorbing, antimicrobial wound dressing and a dressing with diagnostic capability to indicate wound status.

CILOA SAS
Website: www.ciloa.fr
Ciloa is an exosome-based R&D powerhouse that customize exosomes to contain any chosen proteins embedded in their membrane & inside their cytosol. Exosomes are naturally tailored in vivo by cells and membrane proteins complexes are sorted with their fully native conformation.
Natural properties of exosomes combined with Ciloa disruptive technology allow to develop I) antibodies against challenging targets, II) exosome-based therapeutic vectors, III) virus & adjuvant free vaccines.

CARAKTERS
Website: www.carakters.com
Carakters is a boutique innovation-focused law firm based in Paris. By using original methods (results chart, risks mapping), Carakters works as project manager for life sciences actors leading innovative projects in drug discovery, connected devices and biotechnologies, with a focus on public-private consortia, industry-academia collaborations and technology transfers. Carakters also acts as R&D contract manager and offers its clients risks assessing tools to protect their confidential assets.

DIVERCHIM CDMO
Website: www.diverchim.com
DIVERCHIM CDMO is a dedicated manufacturer of Active Pharmaceutical Ingredients required in small quantities (From tens of grams up to hundreds of kilograms). Based on its expertise in terms of chemical synthesis as well as documentation and regulatory aspects for commercial API manufacture, DIVERCHIM has developed over the last years its offer for pre-clinical and clinical needs for biotech and pharma companies.

DIVERCHIM CDMO
Website: www.diverchim.com
DIVERCHIM CDMO is a dedicated manufacturer of Active Pharmaceutical Ingredients required in small quantities (From tens of grams up to hundreds of kilograms). Based on its expertise in terms of chemical synthesis as well as documentation and regulatory aspects for commercial API manufacture, DIVERCHIM has developed over the last years its offer for pre-clinical and clinical needs for biotech and pharma companies.

CITOXLAB
Website: www.citoxlab.com
With nine facilities located in France, Canada, the US, Denmark and Hungary, Citoxlab offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies. Citoxlab carries out studies in general and reproductive toxicology, immunology, pharmacology and preclinical and clinical bioanalysis/biomarkers. With Solvo joining the Group, products and services in the field of transporters and DDI are now available.
**Eurasanté**  
Website: www.eurasante.com  
Eurasanté is an incubator, a technology transfer tool and a cluster manager all at once, in the biotech, medtech, nutrition and healthcare fields in Northern France. It helps French and foreign companies, entrepreneurs, scientists and clinicians with their innovations and development projects. The regional network includes more than 1,000 companies working in the Life Sciences and Healthcare fields. The Health field in the Hauts-de-France region has a total of 28,000 employees.

**E-ZYVEC**  
Website: www.e-zyvec.com  
e-Zyvec is your new expert in DNA vector design and production. Using our proprietary DNA assembly technology we modularly assemble any kind of vector to fit your specific requirements. We provide services for genome editing, protein or cell engineering, multiple gene expressions. We can also handle any custom demand in vector creation. You design your experiment, we create the fitting tools. We are here to set your scientific ingenuity free!

**FGK Clinical Research Gmbh**  
Website: www.fgk-cro.com  
FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization with offices in Germany (HQ), Poland, Czech Republic, Hungary and UK. We provide full service for Phase I-IV clinical studies. FGK has the right size to handle multi-country, multi-center studies with hundreds of patients or single country studies with a few patients, but is still small enough to guarantee a personal service to the sponsor.

**Firalis**  
Website: www.firalis.com  
Firalis is a biotechnology company with a mission to improve disease outcome, therapeutic decisions and generate savings in healthcare through biomarker discovery, development and regulatory qualification that ultimately leads to biomarker-based diagnostics. Firalis develops and markets RUO (Research-use-only) and IVD (In-vitro-diagnostic) kits in the field of cardiovascular, inflammatory, autoimmune and neurology disorders.
GEM FORLAB  STAND D9
Website: www.gemforlab.com
GEM FORLAB is a scientific service provider devoted to supporting companies belonging to the Life Sciences field. GEM FORLAB services are aimed to solve problems linked to quality, safety, efficacy of products/compounds subjected to development phase and to identify customized solutions to specific R&D issues. Thanks to its scientific platforms, the quality system, the competences and the versatility of the team to meet customer needs, GEM FORLAB is the partner of choice of company which requires the capability to manage and solve complex problems following regulatory requirements.

GET-INRA TRANSFERT  STAND D1
Website: www.get.genotoul.fr/get-it/
GeT-IT provides genomics services based on the knowledge and expertise of the French National Institute for Agricultural Research (INRA). Our service allows us to offer multi-technology approaches to answer some biological questions. We are able to perform the complete workflow in-house from the samples to the data analysis thanks to our own instrumentation (rapidity and flexibility) and thanks to a team dedicated to industrials and private companies.

HIRSCH & PARTNERS  STAND A4
Website: www.hirsch-iplaw.com
Hirsch & Partners is an Intellectual Property law firm set up in 1968 providing worldwide full IP services (patent, trademarks, copyright, designs & licensing), allowing clients to meet their intellectual property needs.

IDF INNOV  STAND F5
Website: www.idfinnov.com
IDF Innov is a private TTO with exclusive rights on technology detection, seeding and commercialization over a vast academic territory in the Paris Metropolitan Area. This territory is strong of more than 20000 researchers, clinicians and PhDs, and hosts the strongest cluster for clinical expertise in France. IDF Innov operates as a seeding funds and is committed to facilitate the due diligences for IP related private-public partnering and start-up creation.

GENOSCREEN  STAND D4/7
Website: www.genoscreen.com
Expertise in genomics and bioinformatics GenoScreen, pioneering company in genomics and bioinformatics, has developed a portfolio of activities devoted to DNA molecule exploration and exploitation.
- Multi-specialist provider serving academic and industrial R&D
- Laboratory of high precision analyses and tests in genomics and microbial metagenomics
- A trusted partner to facilitate and accelerate R&D projects
- Provider of solutions and tools dedicated to the microorganism’s detection and analysis

HCS PHARMA  STAND D4/2
Website: www.hcs-pharma.com
HCS Pharma provides services in pre-clinical in vitro research in high content cell imaging (HCS/HCA). Expertise:
- In vitro tests in pharmacology & toxicology in 2D & in 3D culture in medium / high throughput
- BIOMIMESYS® (proprietary technology for 3D cell culture): unique, natural & versatile scaffold based on hyaluronic acid, biofunctionalized with other extracellular matrix components
- Onco-Neuro-Hepato-Adipo-Dermato-Microbiota-Antibio-Tox-quantitative Imaging
- Human & animal Health

ID2SANTÉ  STAND C4
Website: www.id2sante.fr
ID2Santé is a technology innovation centre operating in the Bretagne region (Western France). It is also the regional representative of the Atlantpole Biotherapies competitiveness cluster. It is in close contact with regional researchers and companies from the health sector and helps forge partnerships to support R&D projects and to develop innovative health products.

IMMUNE INSIGHT  STAND D4/4
Website: www.immune-insight.com
Immune insight is a CRO which carries ex-vivo and in-vivo preclinical assessment of new active molecules on the immune system in the fields of Cancer, Autoimmune and Inflammatory diseases. Immune Insight has a strong expertise in Treg full analysis but provides also a full range of services including phenotypic, metabolic, functional, recruitment and conversion analysis of several other human immune cells (monocytes, NK, macrophages, B and T cells, Neutrophils...).
InBrain Pharma is a biotechnology startup, spin-off from academic laboratory, developing innovative solutions against neurodegenerative diseases based on Brain Infusion. Brain infusion is the direct administration of drug inside the central nervous system. Controlled administration in the CNS allows a precise, continuous and targeted administration which increases the efficiency and the safety of the treatments. Our first patented technology is administration of dopamine for Parkinson’s disease.

The CALYM Carnot Institute brings together 15 research teams specialized in lymphoma, first blood cancer. This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offering: from the identification of new biological targets to registration clinical trials.

Curie Cancer is built on the expertise of Institut Curie (3200 people), a leading comprehensive cancer center in Europe and a world-renowned hospital group. Curie Cancer offers to industrial partners the ability to setup research collaborations from therapeutic target identification to clinical validation.

The Chimie Balard Cirimat Carnot Institute provides companies with R&D support in Chemistry, Materials and Processes. We offer innovative solutions to our partners, drawing upon our expertise in green chemistry and processes and in materials with enhanced properties. The comprehensive coverage by our research groups and the access to four state-of-the-art technological platforms allows us to meet any challenge from the energy, health, cosmetics and transport industries.

Carnot Institute Livestock Industry for the Future provides R&D competences to livestock sector businesses, mobilizing three main levers for multiefficient, sustainable and profitable farming: health, nutrition and breeding systems and animal genetics. It brings together actors from agro-veterinary research from INRA and its academic partners with an international visibility and three Agricultural Technical Institutes leaders in the breeding services.

The ICM Carnot Institute is comprised of a research center, a center for clinical investigation and an incubator for start-ups dedicated to finding solutions for diseases and disorders of the central nervous system. Headquartered in a 22,000 sqm building equipped with the latest technological core facilities, our goal is to promote strong partnerships as a means to accelerate translational research and respond to industry actors unmet needs.

As a private subsidiary of Inserm, Inserm Transfert manages economic and societal value creation and the transfer of knowledge from Inserm research laboratories to companies contributing to promote human health innovation.

The M.I.N.E.S Carnot Institute draws its strength from its motivation to break down scientific barriers.
The Institut Carnot Technologies Numériques @ UPSaclay (TN @ UPSaclay), spearheaded by List, an institute of CEA Tech, conducts smart digital systems R&D covering four main areas: Technologies for manufacturing, Cyber-Physical Systems, Data intelligence, Technologies for personalized medicine. At the crossroads of basic research and industrial R&D, this work addresses the field of information and communication science and technology.

The Voir et Entendre Carnot Institute represents one of the most important centers in neurosensory research. It harbors, aside from the research center, a clinical investigation center, a rare disease reference center and an incubator. The institute is designed as a place of exchange gathering on the same site patients, clinicians, researchers and industrials in order to accelerate technological innovations, while bringing solutions to unmet needs of people with visual and hearing impairments.

The Carnot SMILES is a public research institute which aims at making the most of the power of applied mathematics, through collaborative research, in order to foster innovation within companies. Made up of multi-disciplinary teams, the institute accompanies its industrial partners in their technological challenges regarding bioscience (among other themes): molecular dynamics simulation, growth of cells population modeling, wound healing modeling, protein-protein interaction, metagenomics.

Meeting consumer expectations with regards to the sensory and nutritional quality of foods as part of a sustainable food process is a major challenge in terms of innovation. As such, the Qualiment® Carnot Institute implements scientific and technological resources required to support companies in their projects in the field of improvement and development of food products.

IPAZ is an intellectual property law firm committed to its clients, who they are and what and their business is. With an entire department fully dedicated to the health sector, specialized in Life Sciences and Biotech, we provide tailor-made solutions and IP services – prosecution, strategy & valuation - for building strong patent portfolios and thereby creating valuable assets.

The toxicology laboratory of Institut Pasteur de Lille, headed by Fabrice Nesslany, performs genotoxicity, mutagenicity, toxicity and endocrine disruptor assessment of many types of substances (human and animal drugs, cosmetics, chemicals, nanomaterials...), under GLP or in screening. Our experts advise you in the choice of the test protocols, the interpretation of the results and follow-up studies. The department is also implicated in national and European research projects.
Microsynth (founded in 1989) is a leading European company in the area of nucleic acid synthesis & analysis. The main activities are divided into following three business areas: DNA/RNA Synthesis, DNA/RNA Analysis and Sequencing, Contract Research/Outsourcing. For almost three decades, the company's objective has been to serve its customers by delivering products and services of the highest quality, on time and with outstanding service.

MethylDetect’s ApS, products help the researchers to study the biology and significance of methylation changes in disease pathology. Our ambition is to bring our technology into routine use in in-vitro diagnostics for early disease detection, disease risk assessment and personalization of the treatment.

Mitologics is an innovative biotechnology company specialized in detection of mitochondrial dysfunctions. The company offers compound screening services on healthy and pathological mitochondria and cultured cells: predictive toxicity assays (MiToxView® and SeaHorse®) to detect mitochondrial-toxic compounds presenting risks in human; efficacy assays to identify tumor specific-compounds and their MoA (MitoPathway®); mitochondrial targeting assays (protection against oxidative stress; MitoXpert®).

NeurATRIS is a French translational research infrastructure dedicated to translational neuroscience and aimed at validating new treatments / biomarkers for neurodegenerative diseases. NeurATRIS gives access to its world-class preclinical / clinical facilities and cutting-edge equipment [neuro-imaging, biotherapy, cell and animal models, behavior, aptamers, etc.] to life science actors through a one-stop shop.

Neuro-Sys is a privileged partner in the pharmaceutical industry and for biotechnological companies developing neuroprotective and neurorehabilitation molecules.
NOVA BIOMEDICAL             STAND C6
Website: www.novabio.us/fr/
Nova manufactures automated analyzers for cell culture and fermentation monitoring. We employ over 1,000 people, with sales and service subsidiaries in eight countries and distributors in more than 90 additional countries. Our modular BioProfile FLEX provides key chemistries and gases and is expandable to include Cell Density and Cell Viability, Osmolality, and IgG or Ph or Phosphate results with the same sample and a single data output stream.

OPEN R&D LITHUANIA             STAND E8-F4
Website: http://apc.mita.it
Open R&D Lithuania network is a platform of cooperation between open access R&D centers of 14 Lithuanian Universities, 13 Public Research Institutes as well as 7 Science and Technology parks. Six of these institutions specialize in Life Sciences and Biotech area and has modern R&D facilities and close collaboration between scientific and clinical units. Concentration of resources allows to create new technologies and products as well as provide R&D services.

OUEST VALORISATION             STAND F5
Website: www.ouest-valorisation.fr
Ouest Valorisation - Office of Technology Transfer [OTT] was created in the “Future Investments” project call managed by Ministry of Higher Education and Research. Its aim: to propose to companies attractive innovation means from the public research. Ouest Valorisation’s team simplifies the access of the companies to research laboratories in order to develop good collaborative projects or to get access to high professional skills and high level scientific equipment.

NUTRITION HEALTH             STAND D4
LONGEVITY CLUSTER
Website: www.nhl-cluster.com
The Nutrition Health Longevity (NHL) Cluster is a dynamic network at the intersection of health, biotechnology and nutrition. The NHL Cluster aims to connect academia and industry partners around R&D projects. It focuses on the fields of prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to gather and support players from the health and food sectors in designing, developing and financing their future products and processes.

ORIGINAL PROCESS             STAND D6
Website: www.original-process.com
Original Process, specialist of the health of the animals digestive microbiota for 40 years. From its own technology FAP®, Original Process develops exclusive Processes for unique ProBioactFAP® products, naturally rich in prebiotic and postbiotic, for a better digestive Health and immunity. Original Process proposes its R&D and regulatory services to the distributors (vet and feed) and produces as well on its own brand name as under private label. For the design product and the evidence efficiency, Original Process develops and pursues its studies (in vitro, preclinical and clinical trials) in collaboration with scientific, medical and vet partners.

PAR’IMMUNE             STAND D4/5
Website: www.parimmune.com
Par’Imune is a French company leveraging 20 years legacy of academic research on a parasite-derived protein, P28GST, to develop therapeutic strategies toward aggressive inflammatory autoimmune diseases. Besides its safety profile validated in several clinical trials, the immunomodulatory potential of P28GST has been demonstrated in preclinical models of inflammatory diseases. Our drug candidate is under evaluation in a Phase 2a clinical trial in Crohn’s disease.

PHARMALEX A.R.C.             STAND A6
Website: www.pharmalex.com
PharmaLex is one of the most experienced providers for Development Consulting, Regulatory Affairs, Quality Management & Compliance and Vigilance, Epidemiology & Risk Management activities, associated with medicinal products and medical devices. Our global teams of experts will take you from early strategic planning and CMC/NC activities to clinical development, via regulatory agency advices towards market approvals and/or product maintenance support.

PICOMTO             STAND F13
Website: www.picomto.com
Picomto provides web and mobile solutions to help pharmaceuticals companies to digitize their Work Instructions and Standard Operating Procedures in compliance with GMP and FDA Standards (21 CFR Part 11). This is a digital and connected tool for making sure your operators have taken into account the latest version of SOP/WISOP to increase your audit trail level. It ensures your processes to be secured, repeatable and allows you to track all the operations with field data collection.
PULSALYS                                STAND F5  
Website: www.pulsalys.fr  
PULSALYS is a French Technology Transfer Office (TTO), created in 2013 with a public funding of 57 M€, committed in detecting high-potential research results from the laboratories of Lyon & St Etienne, and turning them into strong innovations for companies, or into high tech startup businesses.

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

PORSOLT                                STAND C8  
Website: www.porsolt.com  
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

POC ISOCEM                        STAND D2  
Website: www.pcmisochem.fr  
PMC Isochem offers contract research, custom manufacturing and catalogue products for Pharmaceutical companies worldwide. Our offer addresses three areas: - CDMO services: GMP industrial exclusive custom synthesis and provides tailor made services from development to production, including route selection. - Drug delivery solutions: TPGS-1000 NF USP for poorly soluble drug formulation and Polypeptides based solution for Nano Encapsulation and Polymer Drug. - Generic APIs: 20 generic API

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

PORSOLT                                STAND C8  
Website: www.porsolt.com  
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

RD-BIOTECH                     STAND C3/1  
Website: www.rd-biotech.com  
RD-Biotech is a French CRO offering a wide range of custom services and products in Biotechnology:
Biproduction & purification: Monoclonal and recombinant antibodies (murine, rat, humanized, Fab, ScFv ...). Recombinant proteins, Plasmids, cells.
Development: Hybridoma, transfection and cell lines, Vector, Chimeric and Humanized antibodies, phage display (mouse, llama)
Analytical services: Immunoassay, OCTET, biocassay
FastELISA kits: IgG quantification (mouse, human, rat), Protein A detection.

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

PORSOLT                                STAND C8  
Website: www.porsolt.com  
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

PORSOLT                                STAND C8  
Website: www.porsolt.com  
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

PORSOLT                                STAND C8  
Website: www.porsolt.com  
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.

POLEPHARMA                      STAND C4  
Website: www.polepharma.com  
Polepharma is the first pharmaceutical alliance in Europe, covering 3 regions (Centre-Val de Loire, Normandie and Ile de France) that ensures 53% of drug production in France. Its network relies on a team of experts who aim at stimulating industrial and economic development of the pharmaceutical industry with actions that promote competitiveness, innovation, attractiveness and the “Made in France”.

PORSOLT                                STAND C8  
Website: www.porsolt.com  
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission. Porsolt provides in vitro assays (high throughput screening, high content analysis, and high content histology) and physiopathological models in multiple species and multiple disease areas, tailored solutions and bespoke model development.
SATT NORD  STAND F5
Website: www.sattnord.fr
SATT Nord is a growth-generating tool for valorisation serving researchers and responding to the economic and societal needs for technology transfer. Thanks to a multidisciplinary team of professionals [experts in the various fields of research, project managers, experts in intellectual property, legal experts], SATT Nord ensures the detection of projects, their maturation and the protection of the intellectual rights and even up to their commercialisation through transfer.

SCIOMICS GMBH  STAND E1
Website: www.sciomics.de
Sciomics offers a high-content analysis services for combined phosphorylation / ubiquitylation and protein analysis to investigate pathway activity, disease mechanisms, drug mode-of-action or discover novel drug targets and biomarkers. Currently, more than 1,000 proteins, many being keyplayers in biomedical pathways are analysed in parallel by our immuno-based antibody array platform. The platform guarantees robust and reproducible results which can easily be translated in clinical assays.

SMALTIS  STAND C3/B
Website: www.smaltis.fr
SMALTIS is a CRO specialized in Microbiology and Molecular Biology. By constructing genetically modified bacteria and providing scientific and technical services to understand the characteristics and mechanisms involving microorganisms we help our clients to accelerate the development of their biological products and drugs. Our areas of expertise are the development of new anti-infective compound, the study of microbiota and the setting-up of tools and methods for Bioproduction process.

SATT SUD-EST  STAND F5
Website: www.sattse.com
SATT Sud-Est is a key player in regional economic development associated with innovation. Its core business – technology transfer – consists of protecting, developing and licensing the results of research from public laboratories in the South & Corsica Regions to the socio-economic world. Its goal is to help companies acquire reliable innovations that are better suited to the industrial challenges they face.

SIMV  STAND E7-F3
Website: www.simv.org
SIMV - French association of animal health industry
The French association for animal health industry (SIMV) represents and federates 40 manufacturers and marketers on the French market of medicines and reagents for pets and for farm animals.

SOLADIS  STAND D5
Website: www.soladis.com
Soladis is a consulting and service company specialized in health data.
We developed our expertise on the three challenges of data :
- collection and storage (through IoT, sensors, biosensors, CRF/eCRF, surveys,...),
- processing and analysis (data management, statistics, biostatistics, data science, machine learning),
- valorization (clinical reports, dashboards, data visualisation, algorithms,...).
Our CRO team can also support pharma, biotech, MD-IVD...clinical studies from A to Z.

SOTERYAH IP  STAND E3
Website: www.soteryah.com
European IP Attorneys, experts in patents, trademarks, and all other intellectual property rights, in terms of acquisition, exploitation and defense, in your country, in Europe and internationally. We may also assist you to remove technological barriers and optimize your production based on technical information interalia from non-enforceable patents.

TREMLIN CARNOT I2C  STAND C1
Website: www.i2c.normandie-univ.fr
The associated Carnot I2C brings together 8 research entities from Normandy on the 2nd territory of the chemical industry in France. With a strong expertise in synthesis, analysis and formulation, I2C capitalizes on this chemistry value chain as a privileged partner to support innovation for the pharmaceuticals, fine chemicals, food, bioresources, cosmetics, energy and environmental sectors industries.
**UNIVERSITY OF BIRMINGHAM**  
Website: www.birmingham.ac.uk  
Research, collaboration and innovation that’s transforming our world for the better. Our researchers work with industry partners from discovery science across the translational spectrum, to improve patients’ lives and positively impact their care. We collaborate with the pharmaceutical, medical diagnostic and medical device sector, along with many biotech companies.

**TREMPLIN CARNOT IMAGINE**  
Website: www.institutimagine.org  
Within Necker-Enfants malades Hospital in Paris, Imagine Associated Carnot’s brings together a large number of genetic diseases’ specialists with the aim to better understand these disorders to better diagnose and treat them. Its patient-centered organization and the close collaboration between clinicians and researchers implement a unique translational model that facilitates research collaborations and the establishment of new therapeutic strategies with the industrial partners.

**XELL AG**  
Website: www.xell.ag  
As a leading company, Xell provides highly-efficient solutions in cell culture technology. With a strong focus on cell culture medium and feed development, we have continuously strengthened our technology. In addition to a broad analytical portfolio, we offer customized formulations and high-performance catalog products for CHO, human and Hybridoma cells including special applications (e.g. transfection, virus production): Chemically defined, animal origin-free and suitable for GMP applications.

**XPRESS BIOLOGICS**  
Website: www.xpress-biologics.com  
Xpress Biologics is a contract development organization specialized in the production of Biologics (proteins, antibody fragments and DNA) for preclinical applications specific to the therapeutic, vaccine and diagnostic markets. Our mission is to enable the transition of projects from R&D to clinical manufacturing. The production scale (from 100 mg to 50 g) and the quality of the biologics (R&D and GLP grade) are adapted for in vitro and in vivo preclinical validation of the biologics.

**XPROCHEM**  
Website: www.xprochem.com  
Xprochem specializes in the chemical synthesis of complex proteins (up to ~400 a.a.) that cannot be produced by recombinant methods or are too difficult to synthesize or purify with an acceptable yield. We can also include a variety of finely targeted substitutions, i.e. glycosylations, pegylations and unnatural amino acids.

**YNCREA / SMMIL-E**  
Website: www.centreoscarlambret.fr/actualites/projets-recherche-laboratoire-smmile  
The Chair Digital System & Life Sciences is created to foster the translation of innovative technology in biology and medicine towards original approaches for early diagnosis and patient monitoring for several pathologies. Within Eurasanté, the Chair represents a stimulating ecosystem for startup development, relying on expertise in BioMEMS (Miniaturized system for biology and health) and Artificial Intelligence. Yncréa and SMMiL-E cross their expertise to launch the chair during Biofit event.

**ZOETIS**  
Website: www.zoetis.com  
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales in more than 100 countries.
Founded in 2009 by regional stakeholders, EUROBIOMED is the Life Science cluster from Southern France. We gather more than 250 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients. Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centers, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.

Our missions:
• Develop the Life Sciences network activity in the South of France (Animation of the innovation community, matchmaking and networking between members, organisation of more than 25 scientific and business events each year, advocacy to third parties [public authorities, international stakeholders], etc.);
• Structuring public-private R&D projects to get funded (Monitoring calls for projects, Identification of public and private partners, Support for project building and financing, Project follow-up until market access);
• Personalised support for life sciences companies growth (Corporate strategy, Fundraising, Business development and international markets, Regulatory compliance, Industrialisation and production, Acceleration programmes, Open innovation programmes, etc.).

Our business areas are new therapeutics, medical devices, diagnostics & Imaging and Digital Health. Eurobiomed is the leader of the European Diagnostic Cluster Alliance and is the first immunology cluster in Europe.

This year, Eurobiomed joins the BioFIT organisers team to speed up the development of the event. No need to wait for the next edition to meet them, you can now go to the exhibition area, at the stand F11, and discover their activities!

By 2050 the world’s population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That’s why we’re seeking to help people stay healthier and more active in later life, be it through more targeted treatments for cancer and cardiovascular conditions, solutions for eye diseases, or ways to keep those with arthritis moving. To find out how our innovations are helping to change lives for the better, visit our website: www.bayer.fr.

EUROBIOMED
Website: www.eurobiomed.org

By 2050 the world’s population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That’s why we’re seeking to help people stay healthier and more active in later life, be it through more targeted treatments for cancer and cardiovascular conditions, solutions for eye diseases, or ways to keep those with arthritis moving. To find out how our innovations are helping to change lives for the better, visit our website: www.bayer.fr.

Improving lives since 1896.
A tradition of advancing science and medicine. Then, now and in the future.

Contact us with your innovation | www.roche.com/partnering
BioValley France is a competitiveness cluster which has for mission to federate, develop and promote health players through innovation. The priorities of the cluster are Medicine, Medical Technologies and e-Health.

BioValley France actively participates in development projects of the health sector and supports its members in their R&D innovation approaches enabling them to access high national and international added-value expertise (regulatory, clinical studies, etc.). It also contributes to the networking of its members and develops the ecosystem’s visibility, in order to boost market access.

BioValley France relies on a dynamic network of French, German and Swiss companies to succeed, as well as leading academic and clinical research, and an integrated network of partners that are key players in innovation.

www.biovalley-france.com  @BiovalleyFrance

Eurasanté is an incubator, a technology transfer tool and a cluster manager all at once, in the biotech, medtech, nutrition and healthcare fields in Northern France. It helps French and foreign companies, entrepreneurs, scientists and clinicians with their innovations and development projects.

The regional network includes more than 1,000 companies working in the Life Sciences and Healthcare fields. The Health field in the Hauts-de-France region has a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories.

In addition, Eurasanté organises 4 international partnering events, which aim to increase and improve interactions between academia and the industry.

www.eurasante.com  @Eurasante

The Nutrition Health Longevity (NHL) Cluster is a dynamic network at the intersection of health, biotechnology and nutrition.

The NHL Cluster aims to connect academia and industry partners around R&D projects. It focuses on the fields of prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to gather and support players from the health and food sectors in designing, developing and financing their future products and processes.

www.nhl-cluster.com  @PoleNSL

Founded in 2009 by regional stakeholders, EUROBIOMED is the Life Science cluster from Southern France. We gather more than 250 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centers, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.

www.eurobiomed.org  @PoleEurobiomed
LILLE AND THE HAUTS-DE-FRANCE REGION,
A REGION OF EXCELLENCE IN THE HEALTHCARE SECTOR

The Lille Region is the 3rd ranked life sciences cluster in France. The main areas of expertise in the Hauts-de-France region are metabolic diseases, ageing diseases, nutrition and blood related products. The pharma-biotech sector in Northern France enjoys the presence of both big companies (AstraZeneca, Bayer, GSK...), a dense network of innovative start-ups (AlzProtect, ImaBiotech, Innobiochips...) and dynamic mid-size biopharmaceutical companies (Diagast, Genfit, Genoscreen, LFB...).

The pharma-biotech sector in the Hauts-de-France region:
- Export turnover of more than €3 billion
- Regional turnover of €6 billion (11% of the €53 billion national turnover)
- 11,600 jobs (11% of jobs in France in this sector)
SAVE THE DATE

Biofit FOSTERING INNOVATION & TRANSFER

The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

NEW DESTINATION

MARSEILLE

7th edition

DECEMBER

10 & 11

2019

1,200 delegates

35+ countries represented

Organised by:

Institutional partners: